Cargando…

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

BACKGROUND: The combination of immune-checkpoint inhibitors with chemotherapy has become the standard of treatment for non-small cell lung cancer (NSCLC) patients. However, the association between therapeutic efficacy and the development of immune-related adverse events (irAEs) remains unclear in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurokawa, Kana, Mitsuishi, Yoichiro, Shimada, Naoko, Kawakami, Yuta, Miura, Keita, Miyawaki, Taichi, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Shibayama, Rina, Nojiri, Shuko, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535983/ https://www.ncbi.nlm.nih.gov/pubmed/36203123 http://dx.doi.org/10.1186/s12885-022-10133-1

Ejemplares similares

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
por: Kurokawa, Kana, et al.
Publicado: (2022)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
por: Miyashita, Yosuke, et al.
Publicado: (2020)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
por: Shimamura, Shoko Sonobe, et al.
Publicado: (2022)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Shiting, et al.
Publicado: (2022)

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines
por: Xu, Shiting, et al.
Publicado: (2023)

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
por: Kato, Motoyasu, et al.
Publicado: (2014)

Cerebral infarction in advanced non-small cell lung cancer: a case control study
por: Kato, Motoyasu, et al.
Publicado: (2016)

Hermansky-Pudlak syndrome-associated pneumothorax with rapid progression of respiratory failure: a case report
por: Kato, Yukari, et al.
Publicado: (2020)

Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
por: Nurwidya, Fariz, et al.
Publicado: (2021)

Severe mediastinitis over a month after endobronchial ultrasound‐guided transbronchial needle aspiration
por: Kurokawa, Kana, et al.
Publicado: (2019)

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
por: Kato, Motoyasu, et al.
Publicado: (2021)

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
por: Nakamura, Kota, et al.
Publicado: (2017)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
por: Hayakawa, Daisuke, et al.
Publicado: (2019)

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
por: Kanamori, Koichiro, et al.
Publicado: (2023)

Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
por: Kurokawa, Kana, et al.
Publicado: (2019)

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
por: Ko, Ryo, et al.
Publicado: (2021)

Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID‐19 infection
por: Tanabe, Yuki, et al.
Publicado: (2022)

SCLC-J1, a novel small cell lung cancer cell line
por: Ohara, Kazuo, et al.
Publicado: (2021)

Case fatality rate considering the lag time from the onset of COVID-19 infection to related death from 2020 to 2022 in Japan
por: Nojiri, Shuko, et al.
Publicado: (2023)

Changes in social environment due to the state of emergency and Go To campaign during the COVID-19 pandemic in Japan: An ecological study
por: Kanamori, Rie, et al.
Publicado: (2022)

The impact of declaring the state of emergency on human mobility during COVID-19 pandemic in Japan
por: Nakamoto, Daisuke, et al.
Publicado: (2022)

Novel indicator for the spread of new coronavirus disease 2019 and its association with human mobility in Japan
por: Kawakami, Yuta, et al.
Publicado: (2023)

Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
por: Ueda, Shoko, et al.
Publicado: (2021)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer
por: Okawa, Sachi, et al.
Publicado: (2019)

Paraspinal muscle involvement in pembrolizumab-associated myositis
por: Nosaki, Yasunobu, et al.
Publicado: (2020)

Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
por: Shukuya, Takehito, et al.
Publicado: (2023)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

COVID-19 pandemic and the international classification of functioning in multiple system atrophy: a cross-sectional, nationwide survey in Japan
por: Haruyama, Koshiro, et al.
Publicado: (2022)

Carcinomatous pleuritis and pericarditis accompanied by pulmonary tuberculosis
por: Hara, Munechika, et al.
Publicado: (2016)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial
por: Hojo, Mariko, et al.
Publicado: (2022)

Risk Factors for Concussion in Under 18, Under 22 and Professional Men's Rugby Union: A Video Analysis of 14,809 Tackles
por: Kawasaki, Takayuki, et al.
Publicado: (2023)

Evaluation of the Safety and Efficacy of Modified Laparoscopic Suture Rectopexy for Rectal Prolapse
por: Takahashi, Rina, et al.
Publicado: (2023)

Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2023)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Differences in Clinical Features in Patients with Acute Coronary Syndrome and Stroke: Japanese Multicenter Registry Results
por: Naito, Ryo, et al.
Publicado: (2018)

Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
por: Miyawaki, Eriko, et al.
Publicado: (2022)

Atherosclerotic Cardiovascular Risk in Japan
por: Nojiri, Shuko, et al.
Publicado: (2017)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r0m50u8d11kq6k4v6vt18as1pg